Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials (Englisch)
- Neue Suche nach: Chen, Yiming
- Neue Suche nach: Lawrence, John
- Weitere Informationen zu Lawrence, John:
- https://orcid.org/0000-0002-9892-2753
- Neue Suche nach: Hung, H. M. James
- Neue Suche nach: Stockbridge, Norman
- Neue Suche nach: Chen, Yiming
- Neue Suche nach: Lawrence, John
- Weitere Informationen zu Lawrence, John:
- https://orcid.org/0000-0002-9892-2753
- Neue Suche nach: Hung, H. M. James
- Neue Suche nach: Stockbridge, Norman
In:
Therapeutic Innovation & Regulatory Science
;
55
, 1
; 197-211
;
2020
-
ISSN:
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials
-
Beteiligte:Chen, Yiming ( Autor:in ) / Lawrence, John ( Autor:in ) / Hung, H. M. James ( Autor:in ) / Stockbridge, Norman ( Autor:in )
-
Erschienen in:Therapeutic Innovation & Regulatory Science ; 55, 1 ; 197-211
-
Verlag:
- Neue Suche nach: Springer International Publishing
- Neue Suche nach: Springer Nature
-
Erscheinungsort:[New York]
-
Erscheinungsdatum:2020
-
ISSN:
-
ZDBID:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
- Neue Suche nach: 44.38
- Weitere Informationen zu Basisklassifikation
-
Schlagwörter:
-
Klassifikation:
BKL: 44.38 Pharmakologie -
Datenquelle:
Inhaltsverzeichnis – Band 55, Ausgabe 1
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
FDA’s New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory ScienceRick Turner, J. et al. | 2020
- 6
-
Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation InitiativeMikita, J. Stephen / Mitchel, Jules / Gatto, Nicolle M. / Laschinger, John / Tcheng, James E. / Zeitler, Emily P. / Swern, Arlene S. / Flick, E. Dawn / Dowd, Christopher / Lystig, Theodore et al. | 2020
- 19
-
Benchmarking Patient Recruitment and Retention PracticesLamberti, Mary Jo / Smith, Zachary / Henry, Rhonda / Howe, Deborah / Goodwin, Melanie / Williams, Amanda / Getz, Kenneth et al. | 2020
- 33
-
Determining Minimum Wear Time for Mobile Sensor TechnologyMcCarthy, Marie / Bury, Denise P. / Byrom, Bill / Geoghegan, Cindy / Wong, Susan et al. | 2020
- 38
-
Choosing a Mobile Sensor Technology for a Clinical Trial: Statistical Considerations, Developments and LearningsRussell, Colleen / McCarthy, Marie / Cappelleri, Joseph C. / Wong, Susan et al. | 2020
- 48
-
Alternative New Mono-scaled Quantitative Benefit–Risk Assessment of Human Papillomavirus Vaccine in JapanMatsumoto, Tomoko / Matsumaru, Naoki / Scuffham, Paul / Neels, Pieter / Tsukamoto, Katsura et al. | 2020
- 56
-
Spatial-Cluster Signal Detection in Medical Devices Using Likelihood Ratio Test MethodHu, Tingting / Huang, Lan / Xu, Jianjin / Tiwari, Ram et al. | 2020
- 65
-
Policy of Multisource Drug Products in Latin America: Opportunities and Challenges on the Application of Bioequivalence In Vitro AssaysMiranda-Pérez de Alejo, Claudia / Aceituno Álvarez, Alexis / Mendes Lima Santos, Gustavo / Fernández Cervera, Mirna / Jung-Cook, Helgi / Cabrera-Pérez, Miguel Ángel et al. | 2020
- 82
-
Factors Related to Conversion from Accelerated to Full Approval for Drugs Approved in the United States Between 2000 and 2016Irisawa, Koji / Kaneko, Masayuki / Narukawa, Mamoru et al. | 2020
- 90
-
Bridging the Gap Between RCTs and RWE Through Endpoint SelectionLoCasale, Robert J. / Pashos, Chris L. / Gutierrez, Ben / Dreyer, Nancy A. / Collins, Toby / Calleja, Alan / Seewald, Michael J. / Plumb, Jonathan M. / Liwing, Johan / Tepie, Maurille Feudjo et al. | 2020
- 97
-
Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint SelectionLoCasale, Robert J. / Pashos, Chris L. / Gutierrez, Ben / Dreyer, Nancy A. / Collins, Toby / Calleja, Alan / Seewald, Michael J. / Plumb, Jonathan M. / Liwing, Johan / Tepie, Maurille Feudjo et al. | 2020
- 98
-
Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC)Ayon Verduzco, Ariana / Yeboah, Kwadwo et al. | 2020
- 111
-
Collection of Post-treatment PRO Data in Oncology Clinical TrialsLundy, J. Jason / Coon, Cheryl D. / Fu, An-Chen / Pawar, Vivek et al. | 2020
- 118
-
Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company PracticeRodier, Céline / Bujar, Magda / McAuslane, Neil / Patel, Prisha / Liberti, Lawrence et al. | 2020
- 129
-
Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk RatioSun, Stephen / Heske, Suzanne / Mercadel, Melanie / Wimmer, Jean et al. | 2020
- 138
-
Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?Coleshill, Matthew J. / Aung, Eindra / Carland, Jane E. / Faasse, Kate / Stocker, Sophie / Day, Richard O. et al. | 2020
- 142
-
Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in PharmacovigilanceLee, Inyoung / Jokinen, Jeremy D. / Crawford, Stephanie Y. / Calip, Gregory S. / Kilpatrick, Ryan D. / Lee, Todd A. et al. | 2020
- 152
-
Mobile Applications (Apps) to Support the Hepatitis C Treatment: A Systematic Search in App StoresRodrigues, Aline Teotonio / Sousa, Camila Tavares / Pereira, João / Figueiredo, Isabel Vitória / Lima, Tácio de Mendonça et al. | 2020
- 163
-
The CECMED Office of Innovation: A Core Initiative to Bolster Novel Pharmaceutical Products-The Cuban ApproachRomeu, Belkis / Perez Cristiá, Rafael et al. | 2020
- 170
-
FDA’s Benefit–Risk Framework for Human Drugs and Biologics: Role in Benefit–Risk Assessment and Analysis of Use for Drug ApprovalsLackey, Leila / Thompson, Graham / Eggers, Sara et al. | 2020
- 180
-
Feasibility of a Hybrid Risk-Adapted Monitoring System in Investigator-Sponsored Trials in CancerKim, Sinae / Kim, YunJung / Hong, YoungLan / Kim, YunOk / Lim, Joon Seo / Lee, JiSung / Kim, Tae Won et al. | 2020
- 190
-
Using Statistical Modeling for Enhanced and Flexible Pharmacovigilance Audit Risk Assessment and PlanningZou, Min / Barmaz, Yves / Preovolos, Melissa / Popko, Leszek / Ménard, Timothé et al. | 2020
- 197
-
Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical TrialsChen, Yiming / Lawrence, John / Hung, H. M. James / Stockbridge, Norman et al. | 2020
- 212
-
Drivers of Start-Up Delays in Global Randomized Clinical TrialsLai, Jennifer / Forney, Leila / Brinton, Daniel L. / Simpson, Kit N. et al. | 2020
- 228
-
Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price NegotiationPulini, Alfredo Aram / Caetano, Gabriela Martins / Clautiaux, Henri / Vergeron, Laure / Pitts, Peter J. / Katz, Gregory et al. | 2020
- 239
-
Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning LettersBramstedt, Katrina A. et al. | 2020
- 245
-
Ensuring Black Lives Matter in Drug DevelopmentFitzsimmons, William E. / Okorie-Awé, Clara et al. | 2020
- 247
-
Patient Contribution to the Development and Safe Use of Medicines During the Covid-19 PandemicPitts, Peter J. / Houÿez, François et al. | 2020